- Scientific breakthrough for non-invasive, automatic, objective diagnosis of PTSD leveraging autonomic biomarkers
- Accuracy of 80% (+/- 1%) for objectively diagnosing subjects with PTSD
- Medibio has exclusive worldwide rights to commercialise the technology
SYDNEY, Australia and MINNEAPOLIS, June 28 (Bernama-GLOBE NEWSWIRE) -- Australian Stock Exchange-listed medical technology company Medibio Limited (MEB or the Company) announces a new research study, conducted at Emory University, Atlanta GA and funded by Medibio, demonstrates that post-traumatic stress disorder (PTSD) can be accurately diagnosed using a non-invasive protocol involving heart rate data and machine learning algorithms. The research was based on technology developed at Emory University and licensed by Medibio.
http://mrem.bernama.com/viewsm.php?idm=29462
No comments:
Post a Comment